Bright Minds Biosciences Inc. - common stock - Mali Tablolar (NASDAQ:DRUG)

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

DRUG

Financials

Bright Minds Biosciences Inc. - common stock

Haberler

Piper Sandler, Bright Minds için hisse hedefini yükseltti

Jefferies, Bright Minds hissesi için epilepsi ilacına güvenerek al önerdi

BTIG, Bright Minds hissesi için hedef fiyatını korudu

Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data

Bright Minds Biosciences 175 milyon dolarlık halka arzını tamamladı

Bright Minds Biosciences closes $175 million public offering

Bright Minds Biosciences halka arzını hisse başına 90 dolar fiyatla belirledi

Bright Minds Biosciences prices public offering at $90 per share

Bright Minds Biosciences 175 milyon dolarlık halka arzını fiyatlandırdı

Bright Minds Biosciences prices $175 million public offering

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

BTIG, Bright Minds Biosciences için hisse fiyat hedefini 147 dolara yükseltti